Navigation Links
Cephalon Announces the Availability of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Treated Obstructive Sleep Apnea, Shift Work Disorder and Narcolepsy
Date:6/1/2009

rization and reimbursement process, Cephalon established the NUVIGIL Reimbursement Hotline. The company is also working with managed care organizations in order to provide greater patient access for NUVIGIL through health plans nationwide.

In addition, this year Cephalon created the CephalonCares(SM) Foundation. CEO Frank Baldino, Jr., said, "We recognize that uninsured patients often cannot afford the costs of medications, especially in these economic times. Therefore, we created the CephalonCares Foundation to provide free medication to eligible patients so that they can access our products when they are in need." More information on the CephalonCares Foundation, eligibility guidelines and the products included in the program can be found at www.cephaloncares.com.

Clinical Development Plans

Cephalon is also exploring the potential for NUVIGIL to treat the symptoms associated with an array of medical disorders. The company recently announced results from a phase three clinical trial of NUVIGIL as a treatment for patients with excessive sleepiness associated with jet lag disorder. Those data are expected to be submitted as part of a supplemental New Drug Application (sNDA) later this year.

In addition, the company has an extensive clinical development program in place to further study the efficacy and safety of NUVIGIL in bipolar depression, the negative symptoms of schizophrenia, cancer treatment-related fatigue and excessive sleepiness associated with traumatic brain injury.

"We are encouraged by what we've seen to date from the clinical development program for NUVIGIL. We believe that our continued research into NUVIGIL will enable us to define the full range of benefits that this medication will be able to provide for patients with a variety of medical conditions," added Dr. Lesley Russell, Executive Vice Pre
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes
2. Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc.
3. Cephalon Acquires Controlling Interest in Arana Therapeutics
4. Cephalon Quarterly Conference Call Invitation
5. Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
6. Cephalon Quarterly Conference Call Invitation
7. Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference
8. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
9. Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
10. Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
11. Ohio Sales Reps Information Launched Massive Government Investigation of Cephalon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Cost/Risk Analysis reports, activity measures and outcomes reporting to monitor ... reduced claim costs and positive return on investment over the ... ... Jacksonville, FL (PRWEB) December 17, 2009 -- HealthScreen ... clinical/claims based cost risk analysis along with personalized nurse care, ...
(Date:12/16/2009)... 17 If proposed health care legislation ... the employer-based insurance system. Approximately 18.4 million Californians ... 65 rely upon employer-based insurance for their health ... versions of reform legislation entail specific requirements for ... employees work for firms that currently comply with ...
(Date:12/16/2009)... of Children with Autism and Other Special Needs, ... Levi Join Ben Stiller to Ring in the Holiday ... At its 13th annual Teddy Bear Ball, The Help ... CEO Brian Goldner received the ... philanthropic leadership and commitment to children,s causes; parent ...
(Date:12/16/2009)... Immucor, Inc. (Nasdaq: BLUD ), a global leader ... industry, today announced that Paul D. Mintz, M.D. has ... director, effective January 1, 2010. ,, Dr. Mintz ... for more than 30 years. He is a tenured ... Virginia School of Medicine. He also serves as director ...
(Date:12/16/2009)... --The most widely used human embryonic stem cell lines ... questions that must be addressed to ensure that all ... to a University of Michigan research team. ,, In ... team analyzed 47 embryonic stem cell lines, including most ... The scientists determined the genetic ancestry of each line ...
Breaking Medicine News(10 mins):Health News:Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 2Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 4Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 5Health News:Immucor Appoints New Board Director 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5
... issue of the Cochrane Library journal concludes //that the three ... and Viagra appear to be safe and effective for men ... medications called phosphodiesterase type 5 (PDE-5) inhibitors. ,Diabetes ... have estimated that the diabetic men are about three times ...
... ‘Careless’ is perhaps too mild a word to describe the women ... yet throw caution to the winds, in life and death matters. ... of four women, do not consider themselves to be at risk ... got together for a research which showed that 70% of women ...
... found that the Schering-Plough fungus-fighter drug - Noxafil, //which ... in protecting patients with crippled immune systems, according to ... of their study were published in the New England ... fungal infections, Noxafil, known generically as posaconazole, also seems ...
... all set to tighten the screws on smoking and ... hearing starting on Jan 23, is scheduled in which ... before the committee. ,Under the original act ... sports and other popular events by tobacco companies is ...
... as though reprieve from prostate cancer is as close as ... estimated 32,000 men who are diagnosed with the disease// annually. ... to the disease every year. ,A novel study ... in the management of prostate cancer. Scientists have found that, ...
... about the usage of cholesterol lowering drugs has revealed ... a means to prevent heart disease; Researchers warn// that ... life-threatening health risks for those suffering vascular disease. ... reducing the risk of heart attack and cardiovascular problems ...
Other Medicine News:Health News:ED Drugs - Safe and Effective for Diabetic Men 2Health News:How Veggie Pros, Tomato and Broccoli, Con Prostate Cancer 2
(Date:12/16/2009)... -- TechniScan, Inc. (OTC Bulletin Board: ... company engaged in the development and commercialization of ... that Joe Pepper, PhD, has been appointed to ... Chairman Ken Hungerford commented, "Joe has extensive experience ... GE OEC Medical and U-Systems, both of whom ...
(Date:12/16/2009)... EVANSTON, Ill., Dec. 16 Naurex Inc., ... for depression and other CNS disorders based on ... that it has initiated a Phase I clinical ... successfully dosed the first subjects in the study. ... (GFPA) selective modulator of the NMDA receptor, is ...
(Date:12/16/2009)... PALO ALTO, Calif., Dec. 16 The ... Intradigm Corporation are delighted to announce the merger ... in the field of RNAi (RNA interference). ... will have multiple RNAi discovery, development and delivery ... and a broad portfolio of intellectual property. ...
Breaking Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 2Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 5Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 6WuXi PharmaTech Appoints Wei Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility Eric Gu as Vice Presid 12715 1WuXi PharmaTech Appoints Wei Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility Eric Gu as Vice Presid 12715 2Transplant drug stimulates immune memory 49553 1Transplant drug stimulates immune memory 49553 2United Nations Secretary General Ban Ki moon to Keynote Rotary Internationals 100th Annual Meeting 49552 1United Nations Secretary General Ban Ki moon to Keynote Rotary Internationals 100th Annual Meeting 49552 2United Nations Secretary General Ban Ki moon to Keynote Rotary Internationals 100th Annual Meeting 49552 3
... Anthera Pharmaceuticals,Inc. today announced it has ... Patheon Inc. The agreements provide for the,large-scale ... expected,to be necessary in preparation for Anthera,s ... Application submission to the Food and Drug,Administration. ...
... Mayo clinic in key role in treatment discovery, ... New York,based company Cytopia Limited (ASX: CYT) announced ... demonstrated potent activity in cells,isolated from patients with ... of diseases where there is over-production of,particular cells ...
Other Medicine Technology:Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials 2JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: